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Enhanced glomerular prostaglandin formation in experimental mem-
branous nephropathy. To determine whether the induction of im-
mune—mediated glomerular injury influences the formation of cyclooxy-
genase products by glomerular cells, we determined prostaglandin E2
(PGE2) and thromboxane B2 (TXB2) (as the stable metabolite of TXA2)
formation in isolated glomeruli of rats with passive Heymann nephritis
(PHN). PHN is a model of membranous nephropathy mediated by
antibody and complement independent of inflammatory cells. Five days
following induction of PHN by injection of heterologous antibody to rat
proximal tubular brush border antigen (Fx1A) rats developed protein-
uria 36.5 34 (controls 3.8 1 mg/day). Treatment with cobra venom
factor, which depleted complement C3 levels to less than 10% of
baseline, prevented the development of proteinuria (6.9 2 mg/day).
The development of subepithelial, glomerular immune—complex depos-
its and proteinuria was associated with a significant stimulation of
glomerular PGE2 (87%) and TXB2 (183%) formation. This increment in
glomerular prostanoid biosynthesis was significantly inhibited (PGE2
increased 22%, TXB2 increased 75%) in animals that were complement
depleted with cobra venom factor. Cobra venom factor had no effect on
glomerular prostanoid formation in normal rats. In additional experi-
ments we tested the hypothesis that TXA2 may contribute to mediation
of proteinuria in PHN. We utilized a thromboxane synthetase inhibitor
UK38485. UK38485 reduced glomercular TXB2 formation by 80%
without influencing glomerular deposition of '251-labeled antibody, and
did not alter levels of urine protein excretion in rats with PHN (control
42 21, UK 38485, 39 24mg/day, P> 0.05). Our data demonstrate
that glomerular injury in rats with PHN is associated with increased
TXB2 and PGE2 production which derives from glomerular cells in
vivo. This stimulatory effect of glomerular immune—deposit formation
on prostanoid synthesis is inhibited by generalized systemic comple-
ment depletion. Our data do not support a pathogenic role for TXB2 in
the mediation of proteinuria in this animal model.
Prostaglandins and thromboxane B2 are local hormones syn-
thesized by glomerular epithelial and mesangial cells [1, 2] as
well as by a variety of circulating inflammatory cells including
neutrophils [3], macrophages [4] and platelets [5]. Prostaglan-
dins and thromboxane have direct vasodilatory or vasoconstric-
tor effects which are believed to modulate glomerular hemody-
namics [reviewed in 6]. Recently it has been demonstrated in
several animal models that induction of immunologic glomeru-
lar injury is associated with an increase in production of
cyclooxygenase products by isolated glomeruli [7—10] or renal
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cortex [11]. These changes in prostanoid formation have been
postulated to account for some of the hemodynamic conse-
quences of immune glomerular injury including decrements in
GFR, renal plasma flow and glomerular filtration of protein [7,
11]. In all animal models studied to date, however, two major
questions have been left unanswered. One is whether the
increased prostanoid production observed in experimental
glomerular disease derives primarily from infiltrating inflamma-
tory cells or is a feature of the glomerular response to immune
injury. A second related question is the relative role of various
inflammatory mediators of immune injury in inducing the in-
creased glomerular prostanoid production reported in these
models. Conversely the role of these prostanoids in mediating
the functional glomerular injury observed is also unclear. We
examined both of these issues by studying the synthesis of
prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) in
glomeruli isolated from rats with the passive Heymann nephritis
(PHN) model of experimental membranous nephropathy. In
PHN glomerular injury has been clearly established to be
mediated by complement activation which occurs as a conse-
quence of in situ subepithelial immune—complex formation, but
is entirely independent of circulating inflammatory cells [12,
13]. Our findings document an increase in prostanoid produc-
tion by intrinsic glomerular cells in response to immune injury
and establish a role for complement activation in mediating this
response, They further demonstrate no effect of selective
inhibition of TXB2 synthesis on the immune glomerular injury
produced in this model.
Methods
Materials
Male Sprague—Dawley rats weighing 170 to 190 g were
obtained from Tyler Laboratories Inc. (Bellevue, Washington,
USA). 3H-PGE2 and 3H-TXB2 were purchased from Du
Pont—New England Nuclear Research Products (Boston, Mas-
sachusetts, USA). PGE2 and TxB2 standards were purchased
from Upjohn (Kalamazoo, Michigan, USA). Indomethacin was
obtained from Sigma Chemicals (St. Louis, Missouri, USA).
Cobra venom factor (CYF) was obtained from Cordis Labora-
tories in Miami, Florida, USA.
Experimental protocols
All studies followed a similar experimental protocol in which
groups of rats had PHN induced as described below. PGE2 and
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TXB2 synthesis were determined in isolated glomeruli 16 hours
and six days following antibody injection. Urine protein excre-
tion was measured from day five to six following antibody
injection. Renal tissue was obtained for morphologic and im-
munofluorescence studies at six days. The following groups of
animals were studied.
PHN. To assess the effects of induction of PHN on glomer-
ular PGE2 and TxB2 synthesis, one group of 18 rats was
subjected to the protocol above without modification. Control
rats received equivalent amounts of non-antibody IgG.
PHN-complement depletion. To determine the effect of
glomerular complement activation by in situ subepithelial im-
mune complex formation on PGE2 and TXB2 biosynthesis, one
group of 11 rats was complement depleted with CVF through-
out the six days of the study. Control rats received CVF
following injection of non-antibody IgG.
Effect of TXB2 inhibition on proteinuria in PHN. A group of
seven rats received the thromboxane synthesis inhibitor UK
38485, 50 mg/kg P0 daily in two divided doses 12 hours apart,
beginning 24 hours before anti-Fx1A antibody injection and
continuing through day six. Controls received UK carrier
(saline) only. To exclude any effect of UK 38485 on glomerular
antibody deposition, an additional group of seven rats treated
with UK 38485 received '251-labeled anti-Fx1A IgG. Glomerular
antibody binding was determined six days later. Control rats
received '251-labeled anti-Fx1A IgG and saline replacing UK
38485.
Experimental procedures
Production of passive Heymann nephritis (PHN). PHN was
induced in male rats (170—190 g) by i.v. injection of 1.0 ml of
sheep anti-Fx lA antibody prepared and characterized as previ-
ously described [13, 14]. Urine protein excretion was measured
on urine samples collected from day five to six following
antibody injection and quantitated by a sulfosalicylic acid
method using a commercial protein standard [13—151. On day
six animals were sacrificed under ether anesthesia, and kidneys
were removed for isolation of glomeruli and measurement of
prostanoid synthesis.
Radiolabeling of anti-FxIA IgG. In order to study the effect
of the thromboxane synthesis inhibitor on glomerular antibody
deposition, anti-Fx1A IgG was prepared from a caprylic acid
precipitate of whole serum [161. Purified IgG was labeled with
1251 utilizing the chloramine T method as modified by Mc-
Conahey and Dixon [17]. Trace amounts of labeled antibody
was mixed with unlabeled antibody IgG prior to removal of 125!
by ion—exchange chromatography on AG1-X8 and extensive
dialysis. The final peparation of '251-anti-FX1A IgG was 89%
precipitable in 10% TCA. The specific activity was 5 x iO
cpm/g protein. Measurement of specific activity was carried
out immediately prior to injection.
Isolation and incubation of glomeruli. Glomeruli were iso-
lated immediately after kidney harvesting by differential sieving
techniques from kidneys that were perfused in vivo with 200 ml
of phosphate buffered saline, pH 7.2, containing 1 unit of
heparin/mI. The procedure for glomerular isolation has been
described in detail elsewhere [13—14]. The isolated glomeruli
were incubated in plastic tubes containing 2 ml of Krebs—ringer
HC03 buffer, pH 7.2, at 37°C for 30 minutes. After centrifu-
gation of the tubes at 1000 g for five minutes at 4°C, the
supernatant was collected on indomethacin and frozen at —70°C
until analysis for PGE2 and TXB2 could be carried out.
Glomeruli were then solubilized in iN NaOH and glomerular
protein content was determined according to the method of
Lowry et al [18]. In studies involving quantitation of glomerular
binding of anti-FxlA IgG, glomeruli were isolated exactly as
described above. In these studies glomeruli were counted
visually in a Fuchs—Rosenthal hemocytometer and deposition
of '251-labeled antibody was determined in a Prias gamma
counter as described in detail elsewhere [14]. Previous studies
have shown no detectable amount of blood borne radioactivity
in glomeruli perfused and isolated by this method [14]. Results
were expressed as micrograms of IgG bound/76,000 glomeruli
[141.
Measurements of PGE2 and TXB2. PGE2 and TXB2 were
determined by direct radioimmunoassay of the supernatants
without prior extraction or chromatographic separation. The
assay procedures, sensitivity and specificity of the antisera used
are described elsewhere [191.
Complement depletion. To study the effect of complement
activation induced by in situ, subepithelial immune—complex
formation on glomerular prostaglandin synthesis, rats were
depleted of complement by injection of cobra venom factor
(CVF), 300 U/kg i.p. beginning the day prior to antibody
injection and followed by daily injections of 100U/kg i.p. for the
duration of the experiment. The protocol followed was that
originally described by Cochrane, Muller—Eberhard and Aiken
[20]. C3 depletion was confirmed by measuring plasma C3
levels by Mancini single radial immunodiffusion [21] immedi-
ately prior to antibody injection and on subsequent days prior to
injection of CVF. Results were expressed as a percentage of
baseline C3 levels determined in each animal prior to CVF
administration, and adequate C3 depletion was taken to be
levels of less than 10% of baseline values. To control for any
possible effect of CVF alone on glomerular prostanoid synthe-
sis, three control rats received similar injections of CVF but did
not receive injections of anti-Fx1A antibody.
Morphologic studies. At the end of each experiment renal
tissue from representative animals was examined by light and
immunofluorescence microscopy. Tissue for light microscopy
was fixed in 4% formaldehyde, and paraffin sections were
stained with periodic—acid—Schiff and hematoxylin and eosin
stains prior to examination to evaluate morphologic changes.
Tissue for immunofluorescence was snap—frozen in dry ice—
isopentane, sectioned and stained as described elsewhere [12,
13]. Antisera utilized included fluorescein—conjugated IgG frac-
tions of antibody to sheep IgG, rat IgG and rat C3 (Cappel
Laboratories, Cochranville, Pennsylvania, USA) and rat C5b-9
neoantigens [22].
Statistical analysis
The data on glomerular prostanoid formation are expressed
as pg/mg glomerular protein per minute incubation time. All
data are given as means SD. Statistical analysis were per-
formed with the unpaired Student's t-test with correction for
multiple comparisons when applicable [23]. A P value of < 0.05
was considered significant.
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Fig. 1. Glomerular TXB2 (U) and PGE2 () production by control rats
and animals with passive Heymann nephritis (PHN). PHN rats were
studied 16 hours and 6 days after anti-FxIA antibody injection. Glomer-
ular prostanoid formation in PHN rats which received cobra venom
factor (CVF) were also determined at day 6 after FxIA application
(PHN + CVF). Data are the means SD. Glomerular prostanoid
formation was significantly higher in PHN rats when compared to
control animals (* P < 0.05, ** P < 0.001). CVF reduced TXB2 and
PGE2 formation significantly in PHN rats when studied at day 6 (PHN
vs. PHN + CVF at day 6, P < 0.01).
Results
Glomerular prostanoid formation in PHN
Control rats six days after injection of normal sheep serum
had normal levels of urine protein excretion (3.8 I mg/24 h).
Renal biopsy showed normal morphology and no glomerular
immune deposits. Glomeruli isolated from control rats six days
after injection of normal sheep serum made 125 37 pg/mg/mm
of POE2 and 64 30 pg/mg/mm TXB2 (Fig. 1). In contrast, rats
with PHN had a significant increase in urine protein excretion
(36.5 34 mg!24 h, P < 0.02 vs. controls) and had characteristic
subepithelial deposits of sheep IgG and rat C3 [13, 14, 22]. Light
microscopic studies revealed no significant morphologic alter-
ations in these animals and no evidence of glomerular inflam-
matory infiltrates, confirming results reported previously by us
in this model [13, 14]. However, glomeruli from PHN rats had
increased production of eicosanoids detectable within 16 hours
(PGE2 163 52 pg/mg/mm, TXB2 97 24 pg/mg/mm) which
increased further at six days (PGE2 234 83 pg/mg/mm; TXB2
181 53 pg/mg/mm) (Fig. 1). The absolute amount of POE2
formed in isolated glomeruli was higher than TXB2.
Effect of complement depletion on glomerular prostanoid
formation
Treatment with CVF reduced serum C3 levels to less than
10% of baseline values when determined by radial immunodif-
fusion at six days in both PHN rats and control animals.
Depletion of serum C3 levels prevented the development of
proteinuria at six days (6.9 2 mg/24 h vs. 36.5 34, P < 0.02)
in rats with PHN, confirming previously reported results [13,
14]. Complement depletion in PHN rats also resulted in a
significant decrease in glomerular prostanoid formation (PGE2
153 37 pg/mg/mm, P < 0.01, TXB2 112 29 pg/mg/mm, P <
0.01) at six days when compared with normocomplementemic
PHN controls (Fig. 1). Glomerular POE2 and TXB2 formation in
complement depleted animals, however, remained somewhat
elevated compared with normal rats. TXB2 formation (but not
POE2) was significantly higher when compared to control rats
(P < 0.05). CVF treatment of normal rats (N = 3) induced a
slight, but insignificant, increase in glomerular PGE2 and TXB2
formation. (Control PGE2 125 37 pg/mg/mm, TXB2 64 30
pg/mg/mm, CVF: PGE2 137 31 pg/mg/mm, TXB2 96 17
pg/mg/mm, P> 0.05).
Effect of TXB2 synthesis inhibition on glomerular prostanoid
formation and proteinuria
PGE2 and TXB2 synthesis was measured in PHN rats six
days after antibody injection and 16 hours after the final dose of
UK 38485. Treatment with the thromboxane synthesis inhibitor
UK 38485 for six days resulted in an 80% decrease in glomer-
ular TXB2 formation in vitro in rats with PHN. UK 38485 did
not influence glomerular PGE2 synthesis (Fig. 2). This marked
reduction of TXB2 synthesis occurred in the absence of any
effect of UK 38485 on glomerular deposition of anti-Fx lA IgG
or on urine protein excretion (Fig. 3). UK 38485 also had no
effect on serum C3 levels or on glomerular deposition of IgG
and C3 as judged by immunofluorescence.
Discussion
The production of immune glomerular injury in the form of
the PHN model of membranous nephropathy in rats was
associated with a significant increase in prostanoid formation by
isolated glomeruli. Increased PGE2 and TXB2 production was
detectable compared to controls within 16 hours of the onset of
glomerular immune deposit formation, and was further in-
creased when measured at six days. TXB2 production was
stimulated to a greater extent than POE2, although the absolute
quantities of PGE2 produced always exceeded those of TXB2.
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Fig. 2. The thromboxane synthesis inhibitor UK 38485 (50 mg/kg body
wr/day) given over 6 days reduced glomerular TXB2 production signf-
icantly (* P < 0.001) in rats with passive Heymann nephritis (PHN).
UK 38485 did not effect glomerular PGE2 formation. Data are means
SD. Symbols are the same as in Figure 1.
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These data document for the first time that the increased
glomerular—prostanoid formation in this form of glomerular
injury must result from enhanced glomerular production of
prostanoids, rather than from contributions to total prostanoid
biosynthesis by circulating inflammatory cells, since in PHN
glomerular injury is entirely dependent on antibody and com-
plement and develops in the absence of circulating inflamma-
tory cells [13, 22, 241. Neutrophils or macrophages are known
to participate in mediating glomerulonephritis in all models
previously studied [7—11, 25—27]. The fact that prostanoid
production in PHN derives entirely from glomeruli may account
for the relatively small magnitude of the increase in prostanoid
synthesis seen compared to other models in which extra—gb-
merular cells probably contribute significantly to the results
observed [7—11].
Our data do not further define the resident glomerular cells
responsible for enhanced prostanoid production. Both glomer-
ular epithelial and mesangial cells have been shown to synthe-
size PGE2 and TXB2 [1, 2]. Since PHN is characterized by
immune complex deposits in an exclusively subepithelial distri-
bution resulting from antibody binding to a glomerular epithelial
cell membrane antigen [12, 28, 29], the epithelial cell would
appear to be a more probable source of the increased prostanoid
synthesis observed. The increased production found on day six
compared to day one is consistent with the on—going increase in
subepithelial immune complex formation which occurs during
that interval in PHN [14].
Since the production of glomerular injury as manifest by
proteinuria in PHN is highly complement—dependent and be-
lieved to require assembly of the C5b-9 membrane attack
complex [22, 30, 31], we further investigated the contribution of
complement activation to the enhanced synthesis of PGE2 and
TXB2 observed by comparing the rates of synthesis in
normocomplementemic PHN controls with PHN rats subjected
to generalized complement depletion induced by CVF. CVF
alone has no effect on glomerular antibody deposition [131 and
did not significantly alter prostanoid synthesis in normal rats
without PHN. However, rats depleted of complement suffi-
ciently to prevent development of proteinuria demonstrated
substantially less increase in glomerular prostanoid synthesis
compared to normocomplementemic controls, although stimu-
lation was not abolished. Thus, complement activation appears
to be an important mediator of enhanced prostanoid synthesis
as well as of proteinuria. The stimulation observed in comple-
ment-depleted animals may reflect residual complement activ-
ity or an effect of antibody deposition alone on this process.
The mechanisms of this complement effect is unclear. Com-
plement activation mediates some angiotensin II independent
vasoconstrictive hemodynamic effects in other models [32, 33]
and may have a similar effect in PHN [34, 351. Reductions in
glomerular plasma flow secondary to complement activation
might explain in part the increase in glomerular production of
vasodilatory PGE2 [19] but would not account for the equiva-
lent increase in TXB2 synthesis. A more attractive explanation
for our findings is that simulation of resident glomerular cells by
exposure to non-lytic concentrations of C5b-9 results in en-
hanced prostanoid production. Increased synthesis of PGE2
and TXB2 has been demonstrated by both glomerular mesangial
[361 and epithelial [37] cells in response to C5b-9 in cell culture
systems. C5b-9 can also stimulate glomerular cell production of
free oxygen radicals [38] which have themselves been shown to
provide a potent stimulus to prostanoid production by whole
glomeruli [39]. Further studies will be required to identify the
role of individual glomerular cell types in this process and to
establish the mechanism of the complement effect.
The contribution of glomerular prostanoid production to
glomerular dysfunction in renal disease remains unresolved and
controversial. Some studies have suggested a correlation be-
tween damage to the gbomerular filtration barrier and TXB2
synthesis suggesting a possible role for TXA2 in mediating
glomerular injury [7, 11, 40]. However, we found in PHN that
inhibition of TXB2 synthesis by over 80% with UK 38485 had no
effect on glomerular antibody deposits, complement activation
or proteinuria. Thus, our data do not suggest any role for TXA2
in mediating glomerular injury in this model. However, they do
not exclude an important role for TXB2 in regulating gbomerular
hemodynamics. Gabbai et al [34] have documented a reduction
of about 25% in single nephron GFR in PHN due primarily to a
reduction in Kf, which is angiotensin II independent and only
partially reversed by complement depletion. TXA2 is a known
stimulus to mesangial cell contraction which may in turn reduce
filtering surface area and thereby Kf [41]. Similar reductions in
GFR have been reported in other animal models of renal disease
where stimulation of TXB2 synthesis resulted in a significantly
increased ratio of TXB2 to vasodilatory prostaglandins [7—9, 40,
42—44]. However, studies by other investigators have con-
cluded that vasodilatory prostaglandins are of greater signifi-
cance than TXA2 in regulating glomerular hemodynamics [81.
Thus the relative physiologic significance of the prostanoids
which are synthesized in increased amounts in response to
immune renal injury remains to be accurately defined.
In conclusion, our observations on glomerular prostanoid
synthesis in normal and complement depleted rats with the
PHN model of membranous nephropathy provide compelling
evidence that the enhanced glomerular production of PGE2 and
TXB2 in this model reflects a response of resident glomerular
cells to immunologic injury, and that this response is mediated
in part by the complement system. However, our results do not
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Fig. 3. Despite reduction of TXB2 formation (see Fig. 2) proteinuria
and glomerular deposition of'251-FxJA were not effected by thrombox-
ane synthesis inhibition. Data are means so.
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confirm a role for TXB2 in mediating glomerular injury in this
model.
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